Somewhere in an NHS trust archive sits a well-evaluated pilot. It ran for eighteen months, met its endpoints, generated a favourable cost-effectiveness case, and was written up with the careful, hedged optimism that health services research demands. Then the funding ended, the project team dispersed to other jobs, and the tool it tested quietly stopped being used. Nobody decided to abandon it. It simply had nowhere to go. Multiply that story by the dozens of promising pilots the NHS commissions every year and you have something close to the defining failure mode of NHS innovation policy, not a shortage of good ideas but an inability to carry them past the point where the funding runs out.
NHS England's fourth Innovation Open Call for cancer, opening to applications in September, is built around that exact problem. Since 2021 the programme has funded three earlier rounds, distributing around £40 million across twenty-one projects and reaching more than 220,000 patients, mostly by fast-tracking late-stage innovations into early detection and diagnostic pathways. This round changes the emphasis. Alongside the familiar £3 million strand for single organisations testing innovations with NHS partners, it introduces a second model worth up to £5 million, aimed squarely at integrated care boards and cancer alliances that want to spread and embed tools already shown to work across several sites. The language used to describe it, funding the change as well as the technology, is the clearest acknowledgement yet that procurement was never the hard part. Adoption was.
That distinction matters more now than it would have a year ago. The National Cancer Plan for England, published in February, set targets that only make sense if this kind of scaling actually happens: meeting cancer waiting time standards by 2029, and getting three quarters of people diagnosed with cancer to be cancer-free or living well with it five years on by 2035. Those figures require AI triage tools, ambient voice technology and diagnostic algorithms to move well beyond the handful of early-adopter trusts that usually pilot them, into routine use across a system that has historically struggled to standardise anything at pace. A GIRFT review of radiotherapy productivity, due to report soon, will add to the pressure to show that innovation funding produces embedded practice rather than case studies.
The outcomes-based, matched-funding structure attached to the ICB strand is a serious attempt to force that outcome. Requiring an independent evaluation partner, and tying the later stages of funding to demonstrated commissioning and decommissioning of legacy services, puts real weight on ICBs at a moment when their capacity is already stretched by consolidation and by the operational demands of winter planning. Whether they can absorb another layer of evaluation and governance responsibility on top of that is an open question, and one the programme's designers seem alert to, given how much of the application process is oriented around partnership with cancer alliances and health innovation networks rather than ICBs acting alone.
There is also a political clock running underneath this. The programme opens in September, six weeks before Rachel Reeves's successor at the Treasury delivers a Budget in which NHS capital and technology funding will again be contested territory. A scheme built to prove that innovation money produces durable, business-as-usual change is a useful argument to have in hand going into that fight, and its success or failure will likely shape how generously future rounds are funded.
None of this guarantees the fourth round will succeed where memory of unused pilots suggests caution is warranted. But the design is more honest than most NHS innovation funding has been. It treats scaling, not invention, as the genuine constraint, and asks ICBs to prove they can hold onto what works rather than simply demonstrating that it works in the first place. For an NHS whose innovation record is littered with good pilots that quietly disappeared, that shift in emphasis is worth watching closely.
